Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL29489145 | 1.00 | CA4 (0.41) | CA4CPT2ACLY | |
| SCHEMBL336805 | 0.98 | CA4 (0.43) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL337213 | 0.98 | CA4 (0.43) | CA4CPT2ACLY | |
| SCHEMBL1767657 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| Water SCHEMBL2956339 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| SCHEMBL18124081 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL6442487 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL2706203 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL2466395 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| SCHEMBL965645 | 0.94 | CA4 (0.48) | CA4CPT2ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858128-B2 | Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight | INTERHEALTH NUTRACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | claimed |
| US-20200138767-A1 | HYDROXYCITRIC ACID COMPOUNDS AND CAPSULE LIQUID DELIVERY | GLYKON TECHNOLOGIES GROUP, LLC (US) | 2020-05-07 | — | — | US | disclosed |
| US-10561630-B2 | Hydroxycitric acid compounds and capsule liquid delivery | GLYKON TECHNOLOGIES GROUP, LLC (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2018080795-A1 | HYDROXYCITRIC ACID COMPOUNDS AND CAPSULE LIQUID DELIVERY | GLYKON TECHNOLOGIES GROUP, LLC (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20180110750-A1 | HYDROXYCITRIC ACID COMPOUNDS AND CAPSULE LIQUID DELIVERY | GLYKON TECHNOLOGIES GROUP, LLC (US) | 2018-04-26 | — | — | US | disclosed |
| EP-2445338-A1 | SYNERGISTIC COMBINATION TO ENHANCE BLOOD GLUCOSE AND INSULIN METABOLISM | Glykon Technologies Group, Llc. (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20110105600-A1 | SYNERGISTIC COMPOSITION OF (-)-HYDROXYCITRIC ACID WITH MONOTERPENE AND A METHOD TO ENHANCE SATIETY | GLYKON TECHNOLOGIES GROUP, LLC (US) | 2011-05-05 | — | — | US | disclosed |
| WO-2011051899-A1 | A SYNERGISTIC COMPOSITION OF (-)-HYDROXYCITRIC ACID WITH MONOTERPENE AND A METHOD TO ENHANCE SATIETY | GLYKON TECHNOLOGIES GROUP, LLC (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2010150072-A1 | SYNERGISTIC COMBINATION TO ENHANCE BLOOD GLUCOSE AND INSULIN METABOLISM | GLYKON TECHNOLOGIES GROUP, LLC. (US) | 2010-12-29 | — | — | WO | disclosed |
| US-20100323031-A1 | Synergistic combination to enhance blood glucose and insulin metabolism | GLYKON TECHNOLOGIES GROUP, LLC (US) | 2010-12-23 | — | — | US | disclosed |
| US-20060025482-A1 | (-)-Hydroxycitric acid for the modulation of angiotensin-converting enzyme | CLOUATRE DALLAS L | 2006-02-02 | — | — | US | disclosed |
| US-20060025483-A1 | (-)-Hydroxycitric acid for protection against soft tissue and arterial calcification | CLOUATRE DALLAS L | 2006-02-02 | — | — | US | disclosed |